0

No votes yet

Preventing Vincristine Sulfate Medication Errors

Lisa Schulmeister
ONF 2004, 31(5), E90-E98 DOI: 10.1188/04.ONF.E90-E98

Purpose/Objectives: To review the clinical pharmacology of vincristine sulfate, describe three types of medication errors associated with its use, and suggest strategies for vincristine sulfate medication error prevention.

References 

Alcaraz, A., Rey, C., Concha, A., & Medina, A. (2002). Intrathecal vincristine: Fatal myeloencephalopathy despite cerebrospinal fluid perfusion. <i>Journal of Toxicology: Clinical Toxicology, 40</i>, 557-561.

al Fawaz, I.M. (1992). Fatal myeloencephalopathy due to intrathecal vincristine administration. <i>Annals of Tropical Paediatrics, 12</i>, 339-342.

Al Ferayan, A., Russell, N.A., Al Wohaibi, M., Awada, A., & Scherman, I. (1999). Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection. <i>Child's Nervous System, 15</i>, 87-89.

American Society of Health-System Pharmacists®. (2004a). Hyaluronidase injection. Retrieved March 3, 2004, from http://www.ashp.org/shortage/hyaluronidase.cfm?cfid=13632878&CFToken=635...

American Society of Health-System Pharmacists®. (2004b). Injectable hyaluronidase approved by FDA. Retrieved July 25, 2004, from http://www.ashp.org/news/showArticle.cfm?cfid=11005067&CFToken=53865529&...

Bain, P.G., Lantos, P.L., Djurovic, V., & West, I. (1991). Intrathecal vincristine: A fatal chemotherapeutic error with devastating central nervous system effects. <i>Journal of Neurology, 238</i>, 230-234.

Berenson, M.P. (1971). Recovery after inadvertent massive overdosage of vincristine (NSC-67574). <i>Cancer Chemotherapy Reports, 55</i>, 525-526.

Berwick, D.M. (2001). Not again! Preventing errors lies in redesign—not exhortation. <i>BMJ, 322</i>, 247-248.

Bleck, T.P., & Jacobsen, J. (1991). Prolonged survival following the inadvertent intrathecal administration of vincristine: Clinical and electrophysiologic analyses. <i>Clinical Neuropharmacology, 14</i>, 457-462.

Boyle, D.A., Schulmeister, L., Lajeunesse, J.D., & Anderson, R.W. (2002). Medication misadventure in cancer care. <i>Seminars in Oncology Nursing, 18</i>, 109-120.

Brown, K.A., Esper, P., Kelleher, L.O., O'Neill, J.E.B., Polovich, M., & White, J.M. (2001). <i>Chemotherapy and biotherapy guidelines and recommendations for practice.</i> Pittsburgh, PA: Oncology Nursing Society.

Casteels-Vann Daele, M., Beirinckx, J., & Baines, P. (1977). Overdosage with vincristine. <i>Journal of Pediatrics, 90</i>, 1042-1043.

Chae, L., Moon, H.S., & Kim, S.C. (1998). Overdose of vincristine: Experience with a patient. <i>Journal of Korean Medical Sciences, 13</i>, 334-338.

Clark, B.S., Gallegos, E., & Bleyer, W.A. (1997). Accidental intramuscular vincristine: Lack of untoward effects and recommendations for management. <i>Medical and Pediatric Oncology, 28</i>, 314-315.

Department of Health. (2003). National guidance on the safe administration of intrathecal chemotherapy. Retrieved March 4, 2004, from http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Clinical Governance/Clinical GovernanceGeneralInformation/ClinicalGovernanceGeneralArticle/fs/en?CONTENT_ID=4031335&chk=FihnsD

Dettmeyer, R., Driever, F., Becker, A., Wiestler, O.D., & Madea, B. (2001). Fatal myeloencephalopathy due to accidental intrathecal vincristine administration: A report of two cases. <i>Forensic Science International, 122</i>, 60-64.

Dorr, R.T., & Alberts, D.S. (1985). Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse. <i>Journal of the National Cancer Institute, 74</i>, 113-120.

Dyer, C. (2001). Doctors suspended after injecting wrong drug into spine. <i>BMJ, 322</i>, 257.

Facts and Comparisons. (2004). <i>Drug facts and comparisons</i> (57th ed.). St. Louis, MO: Author.

Fernandez, C.V., Esau, R., Hamilton, D., Fitzsimmons, B., & Pritchard, S. (1998). Intrathecal vincristine: An analysis of reasons for recurrent fatal chemotherapy error with recommendations for prevention. <i>Journal of Pediatric Hematology/Oncology, 20</i>, 587-590.

Ferner, R.E. (2000). Medication errors that have led to manslaughter charges. <i>BMJ, 321</i>, 1212-1216.

Gaidys, W.G., Dickerman, J.D., Walters, C.L., & Young, P.C. (1983). Intrathecal vincristine. Report of a fatal case despite CNS washout. <i>Cancer, 52</i>, 799-801.

Gensia Sicor Pharmaceuticals, Inc. (1999). Vincristine sulfate injection [Package insert]. Irvine, CA: Author.

Greuter, W., McNeill, J., Barrie, F.R., Burdet, H.M., Demoulin, V., Filgueiras, T.S., et al. (Eds.). (1999). International code of botanical nomenclature. Retrieved March 5, 2004, from http://www.bgbm.org/iapt/nomen clature/code/SaintLouis/0000St.Luistitle.htm

Grush, O.C., & Morgan, S.K. (1979). Folinic acid rescue for vincristine toxicity. <i>Clinical Toxicology, 14</i>, 71-78.

Hoffman, J.M., & Prouix, S.M. (2003). Medication errors caused by confusion of drug names. <i>Drug Safety, 26</i>, 445-452.

Institute for Safe Medication Practices. (1998, September 23). Accidental administration of IV meds intrathecally. <i>ISMP Medication Safety Alert, 3</i>(19), 1.

Institute for Safe Medication Practices. (2000, April 5). Pain, paralysis, and knowledge of impending death from intrathecal vincristine. <i>ISMP Medication Safety Alert, 5</i>(7), 1-2.

Institute for Safe Medication Practices. (2003, April 8). Fatal reports of intrathecal vincristine continue. <i>ISMP Medication Safety Alert, 8</i>(7), 4.

Iqbal, Y., Abdullah, M.F., Tuner, C., & Al-Sudairy, R. (2002). Intrathecal vincristine: Long-term survivor of potentially fatal chemotherapy error. <i>Annals of Saudi Medicine, 22</i>, 108-109.

Jochimsen, P.R. (1982). Subacute vincristine toxicity following five consecutive daily doses. <i>American Journal of Clinical Oncology, 5</i>, 437-441.

Kaufman, I.A., Kung, F.H., Koenig, H.M., & Giammona, S.T. (1976). Over-dosage with vincristine. <i>Journal of Pediatrics, 89</i>, 671-674.

Kosmidis, H.V., Bouhoutsou, D.O., Varvoutsi, M.C., Papadatos, J., Stefanidis, C.G., Vlachos, P., et al. (1991). Vincristine overdose: Experience with 3 patients. <i>Pediatric Hematology and Oncology, 8</i>, 171-178.

Kwack, E.K., Kim, D.J., Park, T.I., Cho, K.R., Kwon, I.H., & Sohn, Y.K. (1999). Neural toxicity induced by accidental intrathecal vincristine administration. <i>Journal of Korean Medical Sciences, 14</i>, 688-692.

Lau, G. (1996). Accidental intraventricular vincristine administration: An avoidable iatrogenic death. <i>Medical Science and Law, 36</i>, 263-265.

Laws, D. (2001). The time has come for non-interchangeability of spinal and epidural equipment with intravascular access ports [Letter to the editor]. <i>British Journal of Anaesthesiology, 86</i>, 903.

Maeda, K., Ueda, M., Ohtaka, H., Koyama, Y., Ohgami, M., & Miyazak, H. (1987). A massive dose of vincristine. <i>Japanese Journal of Clinical Oncology, 17</i>, 247-253.

Manelis, J., Freundich, E., Ezekiel, E., & Doron, J. (1982). Accidental intrathecal vincristine administration. Report of a case. <i>Journal of Neurology, 228</i>, 209-213.

Mayne Pharma (USA Inc.). (2004). Vincristine sulfate injection [Package insert]. Paramus, NJ: Author.

Meggs, W.J., & Hoffman, R.S. (1998). Fatality resulting from intraventricular vincristine administration. <i>Journal of Toxicology: Clinical Toxicology, 36</i>, 243-246.

Menzel, E.Z., & Farr, C. (1998). Hyaluronidase and its substrate hyaluronan: Biochemistry, biological activities and therapeutic uses. <i>Cancer Letters, 131</i>(1), 3-11.

Olcay, L., & Safak, T. (2003). Inadvertent intramuscular administration of vincristine: Lack of untoward effects without any treatment except administration of hot compresses. <i>Pediatric Hematology and Oncology, 20</i>, 427-428.

Root, T., & the British Oncology Pharmacy Association. (2001). Medical errors. Appropriate training should avoid accidental intrathecal injection of vincristine [Letter to the editor]. <i>BMJ, 322</i>, 1423.

Rowinsky, E.K., & Donehower, R.C. (2001). Antimicrotubule agents. In B.A. Chabner & D.L. Longo (Eds.)<i>Cancer chemotherapy and biotherapy: Principles and practice</i> (3rd ed., pp. 329-372). Philadelphia: Lippincott Williams and Wilkins.

Schochet, S.S., Lampert, P.W., & Earle, K.M. (1968). Neuronal changes induced by intrathecal vincristine sulfate. <i>Journal of Neuropathology and Experimental Neurology, 27</i>, 645-658.

Schulmeister, L. (1999). Chemotherapy medication errors: Descriptions, severity, and contributing factors. <i>Oncology Nursing Forum, 26</i>, 1033-1042.

Shepherd, D.A., Steuber, C.P., Starling, K.A., & Fernbach, D.J. (1978). Accidental intrathecal administration of vincristine. <i>Medical and Pediatric Oncology, 5</i>, 85-88.

Slyter, H., Liwnicz, B., Herrick, M.K., & Mason, R. (1980). Fatal myeloencephalopathy caused by intrathecal vincristine. <i>Neurology, 30</i>, 867-871.

Stefanou, A., & Dooley, M. (2003). Simple method to eliminate the risk of inadvertent intrathecal vincristine administration [Letter to the editor]. <i>Journal of Clinical Oncology, 21</i>, 2044.

Stones, D.K. (1998). Vincristine overdosage in paediatric patients [Letter to the editor]. <i>Medical and Pediatric Oncology, 30</i>, 193.

Thomas, L.L., Braat, P.C., Somers, R., & Goudsmit, R. (1982). Massive vincristine overdose: Failure of leucovorin to reduce toxicity. <i>Cancer Treatment Reports, 66</i>, 1967-1969.

U.S. Food and Drug Administration. (2004). Listing of approved oncology drugs with approved indications. Retrieved March 5, 2004, from http://www.fda.gov/cder/cancer/druglistframe.htm

Wakem, C.J., & Bennett, J.M. (1975). Inappropriate ADH secretion associated with massive vincristine overdosage. <i>Australian and New Zealand Journal of Medicine, 5</i>, 266-269.

Williams, M.E., Walker, A.N., Bracikowski, J.P., Garner, L., Wilson, K.D., & Carpenter, J.T. (1983). Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeutic error. <i>Cancer, 51</i>, 2041-2047.

Williams, R.L. (2002). Reducing medical errors: A review of innovative strategies to improve patient care. Retrieved March 5, 2004, from http://www.usp.org/patientSafety/briefsArticlesReports/testimony/rlwTest... 2003-05-08.html

Womer, R.B., & Bickert, B. (2003). In reply: Simple method to eliminate the risk of inadvertent intrathecal vincristine administration [Letter to the editor]. <i>Journal of Clinical Oncology, 21</i>, 2044.

Woods, K. (2001). <i>The prevention of intrathecal medication errors. A report to the chief medical officer.</i> London: Department of Health.

Zaragoza, M.R., Ritchey, M.L., & Walter, A. (1995). Neurologic consequences of accidental intrathecal vincristine: A case report. <i>Medical and Pediatric Oncology, 24</i>, 61-62.